Reviewed by
Research published in the peer-reviewed Journal of Diabetes, Obesity and Metabolism demonstrates that UK-based patients on Juniper’s digital weight loss program experienced significant weight loss.
Patients lost an average of 10.73% of their total body weight in 5 months
Among the participants who completed the study, 82.36% lost at least 5% of their baseline weight, 52.07% lost at least 10%, and 23.22% lost at least 15%.
This study’s care continuity claims are the first of their kind. While weight loss outcomes are important when assessing the success of a program, it’s vital that patients feel supported by their multidisciplinary team throughout their care journey.
In this study, participants made use of an app, which provided quick access to the team of healthcare professionals managing their treatment. This was a particularly reassuring feature for those who required support to manage any potential unpleasant side effects.
Patients maintained ongoing contact with their support team, receiving coaching on making and maintaining the healthy lifestyle changes required to achieve long-term weight loss. The average patient received five messages per month from their multidisciplinary care team, with the median response time to adverse events being 14 hours.
This study reported a relatively high drop-out rate, meaning that several patients were not included in the final analysis because they didn't satisfy the study criteria. This is a common finding in studies of real-world chronic care interventions, as everyday challenges such as work and family commitments affect a patient's capacity to upload data within a specific study timeframe.
To gain a proper understanding of Juniper drop-out patterns, investigators conducted a dedicated adherence study, published in the Journal of Community Medicine & Public Health.
This study found that the average Juniper patient stays on the program for six months (183 days).
The most common reasons for discontinuation were program cost (38.7%), dissatisfaction with results (16.8%), intolerable side effects (15.4%), weight loss goal achieved (7.3%) and temporary hiatus/going on holiday (5.6%).
Medical Research Lead
Eucalyptus
Clinical Director
Eucalyptus